
Intimacy
PT-141
Intimate wellness
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.
About PT-141
Bremelanotide activates melanocortin receptors in the brain to support sexual desire and function.
How it works
PT-141 (Bremelanotide) activates melanocortin-4 receptors in the brain. Unlike Viagra/Cialis (which work on blood flow), PT-141 works on the central nervous system to enhance desire. Effective for both men and women.
Clinical evidence
PT-141 (bremelanotide) was FDA-approved in 2019 under the brand Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT trials (Kingsberg et al., Obstet Gynecol 2019) showed statistically significant improvements in desire and reductions in distress vs placebo. Earlier studies in men with erectile dysfunction (Diamond et al., J Sex Med 2006) showed efficacy distinct from PDE5 inhibitors — PT-141 works centrally on melanocortin pathways rather than peripherally on vasodilation, making it useful in patients who don't respond to Viagra or Cialis or whose primary concern is desire rather than erectile function.
Benefits
Dosing
Your prescribing physician determines the right dose, schedule, and how it's administered — based on your goals, medical history, and lab work. Your personalized protocol is provided after your consultation.
Important safety information
+
Possible side effects
Do not use if you have
If you experience severe side effects, call 911 or go to your nearest emergency room.
Frequently asked about PT-141
Most patients notice early effects within 2-4 weeks, with full benefits building over 8-12 weeks of consistent use. Individual response varies based on your goals, baseline health, and dose.
References
- Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT) · Obstetrics & Gynecology (2019) · PMID 31403597
- Diamond LE, Earle DC, Rosen RC, et al.. Co-administration of bremelanotide with sildenafil in male subjects with erectile dysfunction · Journal of Sexual Medicine (2006) · PMID 16839324
- Pfaus JG, Sadiq A, Spitsin S, Douglas SD. Melanocortin receptors and the regulation of sexual function · International Journal of Impotence Research (2008) · PMID 18548080
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Read more about PT-141
Get started today
Ready to start with PT-141?
Free assessment. Licensed physicians. Money-back guarantee if not approved.



